Floatz logo

pf-06865571

Non-Alcoholic Fatty Liver Disease (NAFLD)

PfizerPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

140 Active assets in the Non-Alcoholic Fatty Liver Disease (NAFLD) cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

pf-06865571 is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
70 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
67 / 100
View asset →
liver disorderDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →